In a report published in May 2010 the UK’s National Institute for Health and Clinical Excellence (NICE) issued its first biosimilar recommendation, saying the biosimilar somatropin offers the same efficacy and safety as originator somatropins.
UK’s NICE issues first biosimilar recommendation
Home/Policies & Legislation | Posted 29/10/2010 0 Post your comment
The guidance recommends somatropin for the treatment of growth failure in children, and includes Sandoz’s Omnitrope (somatropin [rDNA] origin) for injection) as one of seven recommended somatropin products – the first time that NICE has recommended the use of a biosimilar.
This is seen as a landmark decision, by Sandoz, who expect the ramifications of which to go far beyond the UK.
The guidance also recommends that, where more than one product is suitable, the least costly option should be chosen.
The guidance issued by the NICE Appraisal Committee noted that Omnitrope had undertaken head-to-head trials with the reference product as part of its regulatory submission to the EMA and found that there were no differences in terms of safety or efficacy between the products.
In August 2010, Omnitrope also received FDA approval for the new indication, the treatment of idiopathic short stature in children.
Omnitrope was the first product to be approved in the EU as a biosimilar, in 2006.
Related article
References
NICE. Human growth hormone (somatropin) for the treatment of growth failure in children (review of NICE technology appraisal guidance 42). Final guidance. 26 May 2010.
Sandoz. NICE issues first biosimilar recommendation, saying Omnitrope® offers same efficacy and safety as other somatropins. 26 May 2010.
Sandoz. Sandoz receives FDA approval for another new indication for Omnitrope and launches Patient Assistance Program. 27 August 2010.
Guidelines
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
EMA concept paper towards a tailored clinical approach in biosimilar development
Public consultation for the modification of the biosimilars regulation in Brazil
Comments (0)
Post your comment